Reducing the risk of venous thromboembolism using apixaban – patient perspectives and considerations. Should more attention be given to females?

References

• GoASMozaffarianDRogerVLAmerican Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics – 2014 update: a report from the American Heart AssociationCirculation2014129339941024446411
   PubMed Web of Science ®Google Scholar
• SteinPDMattaFMusaniMHDiaczokBSilent pulmonary embolism in patients with deep venous thrombosis: a systematic reviewAm J Med2010123542643120399319
   PubMed Web of Science ®Google Scholar
• ManfrediniRPortaluppiFGrandiEFersiniCGalleraniMOut-of-hospital sudden death referring to an emergency departmentJ Clin Epidemiol19964988658688699205
   PubMed Web of Science ®Google Scholar
• FabbianFGalleraniMPalaMIn-hospital mortality for pulmonary embolism: relationship with chronic kidney disease and end-stage renal disease. The hospital admission and discharge database of the Emilia Romagna region of ItalyIntern Emerg Med20138873574023247683
   PubMed Web of Science ®Google Scholar
• KonstantinidesSVTorbickiAAgnelliGTask Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)2014 ESC guidelines on the diagnosis and management of acute pulmonary embolismEur Heart J20143543303330693069a3069k25173341
   PubMed Web of Science ®Google Scholar
• HuttenBAPrinsMHDuration of treatment with vitamin K antagonists in symptomatic venous thromboembolismCochrane Database Syst Rev20061CD00136716437432
   PubMedGoogle Scholar
• Di MinnoASpadarellaGTufanoAPriscoDDi MinnoGEnsuring medication adherence with direct oral anticoagulant drugs: lessons from adherence with vitamin K antagonists (VKASs)Thromb Res2014133569970424525314
   PubMed Web of Science ®Google Scholar
• ChatterjeeSSardarPGiriJSGhoshJMukherjeeDTreatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patientsMayo Clin Proc201489789690724996233
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMZuehlsdorfMMueckWBody weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjectsJ Clin Pharmacol200747221822617244773
   PubMed Web of Science ®Google Scholar
• UpretiVVWangJBarrettYCEffect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjectsBr J Clin Pharmacol201376690891623488672
   PubMed Web of Science ®Google Scholar
• VersoMAgnelliGPrandoniPPros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancerIntern Emerg Med201510665165625840679
   PubMed Web of Science ®Google Scholar
• HanemmjerSSodihardjoFHorikxATrends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the NetherlandsInt J Clin Pharm20153761128113526243531
   PubMed Web of Science ®Google Scholar
• SantaluciaPFranchiCDjadeCDGender differences in drug use in hospitalized elderly patientsEur J Intern Med201526748349026209883
   PubMed Web of Science ®Google Scholar
• AgnelliGBullerHRCohenAOral apixaban for the treatment of acute venous thromboembolismN Engl J Med2013369979980823808982
   PubMed Web of Science ®Google Scholar
• AgnelliGBullerHRCohenAApixaban for extended treatment of venous thromboembolismN Engl J Med2013368869970823216615
   PubMed Web of Science ®Google Scholar
• GoldhaberSZLeizoroviczAKakkarAKApixaban versus enoxaparin for thromboprophylaxis in medically ill patientsN Engl J Med2011365232167217722077144
   PubMed Web of Science ®Google Scholar
• LassenMRRaskobGEGallusAPineoGChenDPortmanRJApixaban or enoxaparin for thromboprophylaxis after knee replacementN Engl J Med2009361659460419657123
   PubMed Web of Science ®Google Scholar
• LassenMRGallusARaskobGEPineoGChenDRamirezLMADVANCE-3 InvestigatorsApixaban versus enoxaparin for thromboprophylaxis after hip replacementN Engl J Med2010363262487249821175312
   PubMed Web of Science ®Google Scholar
• LevineMNGuCLiebmanHAA randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancerJ Thromb Haemost201210580781422409262
   PubMed Web of Science ®Google Scholar
• LassenMRDavidsonBLGallusAPineoGAnsellJDeitchmanDThe efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacementJ Thromb Haemost20075122368237517868430
   PubMed Web of Science ®Google Scholar
• Botticelli Investigators, Writing CommitteeBullerHDeitchmanDPrinsMSegersAEfficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging studyJ Thromb Haemost2008681313131818541000
   PubMed Web of Science ®Google Scholar
• LassenMRRaskobGEGallusAPineoGChenDHornickPADVANCE-2 investigatorsApixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trialLancet2010375971780781520206776
   PubMed Web of Science ®Google Scholar
• NakamuraMNishikawaMKomuroIApixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study)Circ J20157961230123625912695
   PubMed Web of Science ®Google Scholar
• BarrettYCWangJKnabbRMohanPApixaban decreases coagulation activity in patients with acute deep-vein thrombosisThromb Haemost2011105118118920941459
   PubMed Web of Science ®Google Scholar
• JiangXCrainEJLuettgenJMSchumacherWAWongPCApixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitroThromb Haemost2009101478078219350128
   PubMed Web of Science ®Google Scholar
• RaghavanNFrostCEYuZApixaban metabolism and pharmacokinetics after oral administration to humansDrug Metab Dispos2009371748118832478
   PubMed Web of Science ®Google Scholar
• SardarPChatterjeeSLavieCJRisk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trialsInt J Cardiol201517927928725464465
   PubMed Web of Science ®Google Scholar
• ImbertiDGalleraniMManfrediniRTherapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgeryJ Thromb Thrombolysis201234220821322466929
   PubMed Web of Science ®Google Scholar
• van der HulleTKooimanJden ExterPLDekkersOMKlokFAHuismanMVEffectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysisJ Thromb Haemost201412332032824330006
   PubMed Web of Science ®Google Scholar
• KakkosSKKirkilesisGITsolakisIAEditor’s choice – efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trialsEur J Vasc Endovasc Surg201448556557524951377
   PubMed Web of Science ®Google Scholar
• ManthaSAnsellJIndirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolismJ Thromb Thrombolysis201539215516524989022
   PubMed Web of Science ®Google Scholar
• KangNSobierajDMIndirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolismThromb Res201413361145115124713109
   PubMed Web of Science ®Google Scholar
• AlotaibiGAlsalehKWuCMcmurtryMSDabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysisInt Angiol201433430130825056161
   PubMed Web of Science ®Google Scholar
• SobierajDMColemanCIPasupuletiVDeshpandeAKawRHernandezAVComparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: a network meta-analysisThromb Res2015135588889625795564
   PubMed Web of Science ®Google Scholar
• PathakRPanditAKarmacharyaPMeta-analysis on risk of bleeding with apixaban in patients with renal impairmentAm J Cardiol2015115332332725527282
   PubMed Web of Science ®Google Scholar
• MahmoudiMSobierajDMThe cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgeryPharmacotherapy201333121333134023625693
   PubMed Web of Science ®Google Scholar
• AminAJingYTrocioJLinJLingohr-SmithMGrahamJEvaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patientsJ Med Econ2014171176377025078794
   PubMedGoogle Scholar
• BauersachsRMGuidelines for the management of cancer and thrombosis – special aspects in womenThromb Res2015135Suppl 1S13S22
   Google Scholar
• VinereanuDStevensSRAlexanderJHClinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trialEur Heart J201536463268327526371113
   PubMed Web of Science ®Google Scholar
• DentaliFAgenoWPomeroFFenoglioLSquizzatoABonziniMTime trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern ItalyThromb Haemost Epub2015917
   Web of Science ®Google Scholar
• ZhangJChenZZhengJBreuschSJTianJRisk factors for venous thromboembolism after total hip and total knee arthroplasty: a meta-analysisArch Orthop Trauma Surg2015135675977225854654
   PubMed Web of Science ®Google Scholar
• Blanco-MolinaAEneaIGadelhaTSex differences in patients receiving anticoagulant therapy for venous thromboembolismMedicine (Baltimore)2014931730931725398066
   PubMed Web of Science ®Google Scholar
• Martín-MartosFTrujillo-SantosJBarrónMGender differences in cancer patients with acute venous thromboembolismThromb Res2015135Suppl 1S12S1525903526
   PubMed Web of Science ®Google Scholar
• LapnerSCohenNKearonCInfluence of sex on risk of bleeding in anticoagulated patients: a systematic review and meta-analysisJ Thromb Haemost201412559560524977286
   PubMed Web of Science ®Google Scholar
• DentaliFSironiAPGianniMGender difference in efficacy and safety of nonvitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation or venous thromboembolism: a systematic review and a meta-analysis of the literatureSemin Thromb Hemost201541777478726408921
   PubMed Web of Science ®Google Scholar
• KneelandPPFangMCCurrent issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolismPatient Prefer Adherence20104516020361065
   PubMed Web of Science ®Google Scholar
• NilssonHGroveELLarsenTBSex differences in treatment quality of self-managed oral anticoagulant therapy: 6,900 patient-years of follow-upPLoS One2014911e11362725415603
   PubMed Web of Science ®Google Scholar
• ForslundTEttermarkBHjiemdahlPComparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillationEur J Clin Pharmacol Epub20151127
   Web of Science ®Google Scholar
• CastellucciLAShawJvan der SalmKSelf-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scaleThromb Res2015136472773126272305
   PubMed Web of Science ®Google Scholar